{"id":40117,"date":"1998-12-01T12:08:00","date_gmt":"1998-12-01T11:08:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/1998\/vertriebsstopp-fuer-tolcapon-tasmar-in-der-eu"},"modified":"1998-12-01T12:08:00","modified_gmt":"1998-12-01T11:08:00","slug":"vertriebsstopp-fuer-tolcapon-tasmar-in-der-eu","status":"publish","type":"post","link":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/vertriebsstopp-fuer-tolcapon-tasmar-in-der-eu\/","title":{"rendered":"Vertriebsstopp f\u00fcr Tolcapon (Tasmar) in der EU"},"content":{"rendered":"<p>Nach der Meldung von z.T. schweren Hepatitis-\u00e4hnlichen Nebenwirkungen mit zwei Todesf\u00e4llen (Assal, F., et al.: Lancet <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&#038;db=PubMed&#038;list_uids=9752821&#038;dopt=Abstract\" target=\"_blank\" rel=\"noopener\">1998, <B>352<\/B>, 958<\/a>) hat das Committee for Proprietary Medicinal Products (CPMP) der EMEA das Ruhen der Zulassung f\u00fcr das adjuvante Anti-Parkinsonmittel Tolcapon (s.a.<a href=\"http:\/\/www.der-arzneimittelbrief.de\/de\/Artikel.aspx?SN=5962\" target=\"_blank\" rel=\"noopener\">AMB 1998, <B>32<\/B>, 53a<\/a>) beschlossen; die Mitgliedsl\u00e4nder wurden aufgefordert, den Vertriebsstopp ab dem 17. November 1998 anzuordnen. Die Hoffmann-La Roche AG hat dies in einem Rote-Hand-Brief mitgeteilt. In den USA jedoch bleibt das Mittel unter einer ge\u00e4nderten Anwendungsinformation weiterhin zugelassen. Wie lange noch?<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Nach der Meldung von z.T. schweren Hepatitis-\u00e4hnlichen Nebenwirkungen mit zwei Todesf\u00e4llen (Assal, F., et al.: Lancet 1998, 352, 958) hat das Committee for Proprietary Medicinal Products (CPMP) der EMEA das Ruhen der Zulassung f\u00fcr das adjuvante Anti-Parkinsonmittel Tolcapon (s.a.AMB 1998, 32, 53a) beschlossen; die Mitgliedsl\u00e4nder wurden aufgefordert, den Vertriebsstopp ab dem 17. November 1998 anzuordnen. [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","footnotes":""},"categories":[1],"tags":[6894],"class_list":["post-40117","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-tolcapon"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Vertriebsstopp f\u00fcr Tolcapon (Tasmar) in der EU - Der Arzneimittelbrief<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/vertriebsstopp-fuer-tolcapon-tasmar-in-der-eu\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vertriebsstopp f\u00fcr Tolcapon (Tasmar) in der EU - Der Arzneimittelbrief\" \/>\n<meta property=\"og:description\" content=\"Nach der Meldung von z.T. schweren Hepatitis-\u00e4hnlichen Nebenwirkungen mit zwei Todesf\u00e4llen (Assal, F., et al.: Lancet 1998, 352, 958) hat das Committee for Proprietary Medicinal Products (CPMP) der EMEA das Ruhen der Zulassung f\u00fcr das adjuvante Anti-Parkinsonmittel Tolcapon (s.a.AMB 1998, 32, 53a) beschlossen; die Mitgliedsl\u00e4nder wurden aufgefordert, den Vertriebsstopp ab dem 17. November 1998 anzuordnen. [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/vertriebsstopp-fuer-tolcapon-tasmar-in-der-eu\/\" \/>\n<meta property=\"og:site_name\" content=\"Der Arzneimittelbrief\" \/>\n<meta property=\"article:publisher\" content=\"http:\/\/www.facebook.com\/derarzneimittelbrief.de\" \/>\n<meta property=\"article:published_time\" content=\"1998-12-01T11:08:00+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2012\/06\/logo_amb_neu.jpg\" \/>\n<meta name=\"author\" content=\"Dennis Hoppe\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dennis Hoppe\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/vertriebsstopp-fuer-tolcapon-tasmar-in-der-eu\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/vertriebsstopp-fuer-tolcapon-tasmar-in-der-eu\\\/\"},\"author\":{\"name\":\"Dennis Hoppe\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a04aadd6db7c06c7464bdbbb5396ed16\"},\"headline\":\"Vertriebsstopp f\u00fcr Tolcapon (Tasmar) in der EU\",\"datePublished\":\"1998-12-01T11:08:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/vertriebsstopp-fuer-tolcapon-tasmar-in-der-eu\\\/\"},\"wordCount\":90,\"keywords\":[\"Tolcapon\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/vertriebsstopp-fuer-tolcapon-tasmar-in-der-eu\\\/\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/vertriebsstopp-fuer-tolcapon-tasmar-in-der-eu\\\/\",\"name\":\"Vertriebsstopp f\u00fcr Tolcapon (Tasmar) in der EU - Der Arzneimittelbrief\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\"},\"datePublished\":\"1998-12-01T11:08:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a04aadd6db7c06c7464bdbbb5396ed16\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/vertriebsstopp-fuer-tolcapon-tasmar-in-der-eu\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/vertriebsstopp-fuer-tolcapon-tasmar-in-der-eu\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/vertriebsstopp-fuer-tolcapon-tasmar-in-der-eu\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vertriebsstopp f\u00fcr Tolcapon (Tasmar) in der EU\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\",\"name\":\"Der Arzneimittelbrief\",\"description\":\"Unabh\u00e4ngige Arzneimittelinformationen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a04aadd6db7c06c7464bdbbb5396ed16\",\"name\":\"Dennis Hoppe\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g\",\"caption\":\"Dennis Hoppe\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vertriebsstopp f\u00fcr Tolcapon (Tasmar) in der EU - Der Arzneimittelbrief","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/vertriebsstopp-fuer-tolcapon-tasmar-in-der-eu\/","og_locale":"de_DE","og_type":"article","og_title":"Vertriebsstopp f\u00fcr Tolcapon (Tasmar) in der EU - Der Arzneimittelbrief","og_description":"Nach der Meldung von z.T. schweren Hepatitis-\u00e4hnlichen Nebenwirkungen mit zwei Todesf\u00e4llen (Assal, F., et al.: Lancet 1998, 352, 958) hat das Committee for Proprietary Medicinal Products (CPMP) der EMEA das Ruhen der Zulassung f\u00fcr das adjuvante Anti-Parkinsonmittel Tolcapon (s.a.AMB 1998, 32, 53a) beschlossen; die Mitgliedsl\u00e4nder wurden aufgefordert, den Vertriebsstopp ab dem 17. November 1998 anzuordnen. [&hellip;]","og_url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/vertriebsstopp-fuer-tolcapon-tasmar-in-der-eu\/","og_site_name":"Der Arzneimittelbrief","article_publisher":"http:\/\/www.facebook.com\/derarzneimittelbrief.de","article_published_time":"1998-12-01T11:08:00+00:00","og_image":[{"url":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2012\/06\/logo_amb_neu.jpg","type":"","width":"","height":""}],"author":"Dennis Hoppe","twitter_misc":{"Verfasst von":"Dennis Hoppe"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/vertriebsstopp-fuer-tolcapon-tasmar-in-der-eu\/#article","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/vertriebsstopp-fuer-tolcapon-tasmar-in-der-eu\/"},"author":{"name":"Dennis Hoppe","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a04aadd6db7c06c7464bdbbb5396ed16"},"headline":"Vertriebsstopp f\u00fcr Tolcapon (Tasmar) in der EU","datePublished":"1998-12-01T11:08:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/vertriebsstopp-fuer-tolcapon-tasmar-in-der-eu\/"},"wordCount":90,"keywords":["Tolcapon"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/vertriebsstopp-fuer-tolcapon-tasmar-in-der-eu\/","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/vertriebsstopp-fuer-tolcapon-tasmar-in-der-eu\/","name":"Vertriebsstopp f\u00fcr Tolcapon (Tasmar) in der EU - Der Arzneimittelbrief","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website"},"datePublished":"1998-12-01T11:08:00+00:00","author":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a04aadd6db7c06c7464bdbbb5396ed16"},"breadcrumb":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/vertriebsstopp-fuer-tolcapon-tasmar-in-der-eu\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/vertriebsstopp-fuer-tolcapon-tasmar-in-der-eu\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/vertriebsstopp-fuer-tolcapon-tasmar-in-der-eu\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/"},{"@type":"ListItem","position":2,"name":"Vertriebsstopp f\u00fcr Tolcapon (Tasmar) in der EU"}]},{"@type":"WebSite","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/","name":"Der Arzneimittelbrief","description":"Unabh\u00e4ngige Arzneimittelinformationen","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a04aadd6db7c06c7464bdbbb5396ed16","name":"Dennis Hoppe","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g","caption":"Dennis Hoppe"}}]}},"_links":{"self":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-json\/wp\/v2\/posts\/40117","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-json\/wp\/v2\/comments?post=40117"}],"version-history":[{"count":0,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-json\/wp\/v2\/posts\/40117\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-json\/wp\/v2\/media?parent=40117"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-json\/wp\/v2\/categories?post=40117"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-json\/wp\/v2\/tags?post=40117"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}